Skip to content

Healing & recoverySkin & hair

Klowverine

KLOW-verine · Klowverine blend · double KLOW

PreclinicalProhibited in sportReviewed 25 Aug 2026

What is in the vial

Components of Klowverine and their share of a standard vial.
CompoundPer vialShare
GHK-CuLargest component by mass and the source of the blue colour. Unchanged from KLOW.50 mg45%
BPC-157Doubled from KLOW. Associated with angiogenesis in animal models.20 mg18%
TB-500Doubled from KLOW. Associated with cell migration through actin binding.20 mg18%
KPVDoubled from KLOW. Anti-inflammatory in cell and animal work.20 mg18%

The ratio is fixed in the vial. Choosing a dose of one component chooses the dose of all the others — you cannot move one without moving them all.

What the contents cost separately

The same masses this vial holds, bought as individual vials, at the cheapest confirmed listing and at the median across vendors. We do not price blend vials themselves — hold this against whatever you are being quoted.

$212$262

for 110 mg across 4 compounds

Cost of each component bought separately
CompoundIn this vialSeparately
GHK-Cu50 mg$22–$27
BPC-15720 mg$60–$70
TB-50020 mg$70–$90
KPV20 mg$60–$75

Buying separately costs more injections and more vials, and buys back the ability to change one dose without changing the others. Prices are read from vendor sites and normalised per milligram; we take no vendor placement. Every listing.

Klowverine is KLOW with BPC-157, TB-500 and KPV each doubled from 10 mg to 20 mg, leaving GHK-Cu at 50 mg. That makes a 110 mg vial at roughly 2.5:1:1:1, against KLOW's 80 mg at 5:1:1:1.

The name is a portmanteau of KLOW and Wolverine, and the formulation follows it: the repair peptides Wolverine is built on, at twice the KLOW share, with KLOW's copper and KPV still there.

It is the least documented blend on this page. Searching the name returns KLOW product listings rather than a specification, and the ratio here is reported community practice rather than a published or manufacturer figure. Treat the composition of any vial you are handed as unconfirmed until the seller states it.

How it works

Four separate mechanisms arriving together, none studied in combination, and no study of this ratio specifically.

GHK-Cu delivers copper for collagen and elastin synthesis.

BPC-157 is associated with angiogenesis in animal models.

TB-500 binds actin and is associated with cell migration.

KPV is a tripeptide fragment of alpha-MSH with anti-inflammatory activity in cell and animal work.

Regulatory status — United States

Not approved anywhere as a mixture or as any of its parts. Sold as a research chemical, and less consistently documented than KLOW — the ratio is reported rather than specified.

Last reviewed 25 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Tissue repair with an anti-inflammatory component

Published review

What the combination is sold for.

EvidenceNo study of the mixture or of this ratio exists. Every component is separately supported by animal or cell-culture work only.

Identity and clearance

Molecule

Class
Pre-mixed blend of four peptides, roughly 2.5:1:1:1 by mass

A 110 mg vial is 50 mg GHK-Cu with 20 mg each of BPC-157, TB-500 and KPV. Reported ratio; no manufacturer specification is published.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 110 mg vialSourceStart this protocol
Commonly described community protocol2.2 mg – 4.4 mgDaily, in courses of 4 to 8 weeksSubcutaneousTotal blend. At 2.5:1:1:1, 2,200 mcg of blend delivers 400 mcg each of BPC-157, TB-500 and KPV alongside 1,000 mcg of GHK-Cu.10–20 uCommunity practiceStart this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Calculator

Work out what to draw

Pre-filled with a 110 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Dose unit
Your syringe
010203040506070809010010 units0.1 mL

Draw to 10 units on a 1 mL U-100 syringe. That is 0.1 mL, containing 2.2 mg of Klowverine.

Concentration22mg / mL
Volume drawn0.1mL
Doses per vial50doses
Per unit220mcg / unit

10 units sits exactly on a printed line.

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

  • Everything from four compounds at oncePublished review

    Unknown

    No human study of the mixture. Each component's own adverse-effect profile applies, and they cannot be separated if something goes wrong.

  • Injection site reactionsCommunity practice

    Commonly reported

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • An injection site that becomes hot, spreading or produces pus.
  • Any new or changing lump. Several components are associated with proliferation in animal models.

Interactions and situations that need care

  • Active or previous cancerAvoid

    Components associated with angiogenesis and proliferation in animal models, none studied in anyone with a malignancy.

  • Wilson's disease or any copper metabolism disorderAvoid

    GHK-Cu delivers copper deliberately and is the largest component.

  • Pregnancy and breastfeedingAvoid

    No safety data for any component, let alone the mixture.

  • Wanting to control the dose of one componentUse caution

    Four compounds at a fixed ratio means four doses chosen at once. Running them separately is the only way to dose them separately.

  • Competing in a tested sportAvoid

    Components are WADA S2, prohibited at all times.

SportProhibited by the World Anti-Doping Agency under S2: Peptide Hormones, Growth Factors, Related Substances, at all times, in and out of competition.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

  • The least documented blend here. The ratio is reported community practice, not a published specification.
  • No study of the mixture, and none of this ratio against KLOW's.
  • Four fixed doses chosen at once. GHK-Cu is still the largest share, at two and a half times any other component.
  • Doubling the repair peptides also doubles what you cannot attribute if you react to it.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

With other peptides

  • KLOWcaution

    This is KLOW with three of its four components doubled. Running both means taking all four twice, at an unclear total.

  • GLOWcaution

    GLOW is three of these four components. Running both means taking GHK-Cu, BPC-157 and TB-500 twice.

  • Wolverinecaution

    Wolverine is BPC-157 and TB-500, both already here at 20 mg. Running both doubles them again.

  • Deadpoolcaution

    Deadpool is three of this blend's four components. Running both means taking BPC-157, TB-500 and KPV twice.

Check this against a whole stack

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

  • Blue solution after reconstitution

    The copper complex, as in GLOW and KLOW.

  • Cloudiness or visible particles

    Discard it.

  • No stated ratio

    This blend is poorly documented and the name is close to KLOW's. Without a stated split you cannot tell which of the two you have, and they differ by twice the repair peptides.

Questions

How is Klowverine different from KLOW?
The GHK-Cu is the same at 50 mg. BPC-157, TB-500 and KPV are each 20 mg rather than 10, making a 110 mg vial instead of 80. Per milligram of blend you therefore get less GHK-Cu and more of everything else.
Where does this composition come from?
Community practice. No manufacturer specification for a blend under this name is published, and searching the name mostly returns KLOW listings. We record the reported ratio and say so rather than presenting it as established.
Can I use a KLOW protocol for it?
Not without redoing the arithmetic. The same volume of a Klowverine vial delivers a different amount of every component, so a dose in units or millilitres carried over from KLOW is wrong in four ways at once.

References

  1. Component evidence for common peptide blends: an assessment of what is known separately

    Preclinical peptide literature, 2024 · Assessment of the separate component literatures

    Cell culture and rodent models

    Every component of the common blends is supported by animal or cell-culture work only. No study has examined any of these combinations as a mixture, so combination evidence is weaker than the single-compound evidence. That is itself preclinical.

  2. Community and vendor practice, unverified

    Vendor listings and community protocols, 2026 · Anecdote

    Self-selected, unverified

    Ratios and doses as vendors sell and users describe them. Ratios vary between sellers, so a blend bought from two vendors is not necessarily the same product.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 25 Aug 2026